相关实验视频

Updated: Jul 2, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

在复发性或不耐药的急性髓性白血病中,Venetoclax与decitabine或azacitidine一起使用

Ian M Bouligny^1,2, Graeme Murray³, Michael Doyel³

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. IMBouligny@mdanderson.org.

Medical oncology (Northwood, London, England)

|February 23, 2024

概括

与低甲基化剂结合的Venetoclax在复发性/耐药性急性髓性白血病 (AML) 中表现有前途. 对于这些低强度策略,ELN 2022指南需要改进,但特定的突变和CCI得分可以指导治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床研究临床研究

背景情况:

复发性或耐药性急性髓性白血病 (AML) 具有严重的治疗挑战,预后不佳.
作为BCL-2抑制剂的Venetoclax在一线治疗中与低强度疗法相结合,可以改善治疗结果.
基于venetoclax的疗法在后期治疗线路中的有效性以及更新的预后指南 (ELN 2022) 的适用性需要进一步研究.

研究的目的:

为了评估venetoclax与decitabine或azacitidine在复发/耐药AML患者的联合疗效.
评估欧洲白血病网 (ELN) 2022年分类对低强度的基于venetoclax的策略的适用性.
识别基因突变和临床因素,以改进预后和指导治疗选择.

主要方法:

用venetoclax和低甲基化剂治疗的复发/耐药AML患者的回顾性分析.
对治疗反应和生存结果的评估,按遗传突变和ELN 2022风险类别分层分层.
应用增量生存计算方法来确定查尔森并发症指数 (CCI) 的预后值.

主要成果:

根据ELN 2022的修订,基于venetoclax的低强度策略的预后预测不足.
患有NPM1和IDH突变的患者表现出更好的反应和生存率.
NRAS,KRAS和FLT3-ITD中的突变与较差的结局有关.
5的CCI得分被确定为死亡风险升高的门.

结论:

为了在复发性/耐药性AML中准确预测基于venetoclax的低强度疗法,需要完善ELN 2022指南.
特定的基因突变 (NPM1,IDH,NRAS,KRAS,FLT3-ITD) 显著影响治疗反应和生存.
CCI评分可以帮助识别那些可能受益于更密切监测或替代治疗方法的患者.

关键词:

在AML,AML就是AML.亚扎西提丁胺是一种阿扎西提丁.德西塔类药物德西塔类药物耐火的耐火的耐火的复发的复发的复发的威尼托克拉克斯 (Venetoclax) 是一个属于威尼托克拉克斯的地区.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...